newwin
Luciann Nguyen
Settings
← Accounts
biotech

Vividion Therapeutics, Inc.

44
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Vividion Therapeutics, Inc.

New trial — A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

New trialNCT06804824
44/100
Opportunity
Commercial fit5/25
Clinical timing20/20
Biomarker need0/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency1/5

New phase 1 trial NCT06804824 posted by Vividion Therapeutics, Inc.: "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 174 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06804824
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
phase 1
—